Insider Transactions in Q3 2025 at Xeris Biopharma Holdings, Inc. (XERS)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Kevin Mc Culloch Officer |
SELL
Other acquisition or disposition
|
Indirect |
2,000
-100.0%
|
-
|
|
Sep 11
2025
|
Marla Persky Director |
SELL
Open market or private sale
|
Direct |
15,500
-9.84%
|
$108,500
$7.72 P/Share
|
|
Aug 28
2025
|
Jeffrey W Sherman Director |
SELL
Open market or private sale
|
Direct |
42,232
-16.15%
|
$295,624
$7.92 P/Share
|
|
Aug 28
2025
|
Jeffrey W Sherman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
47,040
+15.25%
|
$282,240
$6.66 P/Share
|
|
Aug 13
2025
|
John Johnson Director |
SELL
Open market or private sale
|
Direct |
107,500
-11.42%
|
$752,500
$7.32 P/Share
|
|
Aug 12
2025
|
Dawn Halkuff Director |
SELL
Open market or private sale
|
Direct |
42,500
-26.98%
|
$297,500
$7.28 P/Share
|
|
Aug 01
2025
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
36,918
-1.37%
|
$184,590
$5.38 P/Share
|
|
Aug 01
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,651
-0.85%
|
$73,255
$5.38 P/Share
|